November 04, 2025

Get In Touch

Afib More Common And Dangerous In Younger People Than Previously Thought, Claims Study

Atrial Fibrillation Study

Atrial Fibrillation in Younger Populations

Atrial fibrillation (Afib), a common type of arrhythmia that is on the rise in people under the age of 65, is more dangerous in this increasingly younger population than previously thought, according to a new study published today in Circulation Arrhythmia and Electrophysiology and authored by physician-scientists at the UPMC Heart and Vascular Institute.

The study, which is among the first to examine a large group of Afib patients younger than 65 in the U.S., found that these younger patients were more likely to be hospitalized for heart failure, stroke or heart attack and had significantly higher rates of comorbidity and mortality, compared to similarly aged and gender-matched people who do not have Afib.

“Common knowledge among cardiologists is that, in people under 65, Afib is extremely uncommon and not detrimental. But there really hasn’t been any data to back that up,” said lead author Dr. Aditya Bhonsale, M.D., M.H.S, a UPMC cardiac electrophysiologist in HVI’s Division of Cardiology who is also an assistant professor of medicine at the University of Pittsburgh.

“At UPMC, we've been seeing a lot more young patients with Afib in recent years and have been interested in understanding the real-world clinical course of these individuals. As a payer-provider with patient records across more than 40 hospitals, UPMC was uniquely positioned to ask this question, which no one has been able to ask before,” Bhonsale added.

Drawing from the electronic health records of 67,221 UPMC patients seeking care for Afib from 2010 through 2019, the researchers found that more than a quarter of them (17,335) were under the age of 65, a stark contrast to the 2% prevalence commonly estimated. The high proportion likely reflects an increasing burden of cardiovascular risk factors in younger Americans, said Bhonsale.

The UPMC team found that over the course of a decade, survival rates for those with the arrhythmia were 1.3 to 1.5 times worse for men with Afib, and 1.82 to 3.16 times worse for women, compared to similarly aged patients who did not have Afib. The patients studied also had high rates of cardiovascular disease risk factors, including:

  • Smoking
  • Obesity
  • Hypertension
  • Sleep apnea

These factors contribute to damaging structural and electrical changes in the heart over time.

“We are optimistic that data from this study will foster future investigation to evaluate optimal therapies for patients with Afib,” said senior author Sandeep Jain, M.D., director of cardiac electrophysiology in HVI’s Division of Cardiology who is also a professor of medicine at the University of Pittsburgh.

Reference

Aditya Bhonsale, Jianhui Zhu, Floyd Thoma, Steve Koscumb, Krishna Kancharla, Andrew Voigt, Jared Magnani, N.A. Estes, Samir Saba, Oscar Marroquin, Suresh Mulukutla and Sandeep Jain, Mortality, Hospitalization, and Cardiac Interventions in Patients With Atrial Fibrillation Aged <65 Years, Circulation: Arrhythmia and Electrophysiology, https://doi.org/10.1161/CIRCEP.123.012143.

Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our Terms of Use, Privacy Policy, and Advertisement Policy.
For further details, please review our Full Disclaimer.

0 Comments

Post a comment

Please login to post a comment.

No comments yet. Be the first to comment!